These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1156 related articles for article (PubMed ID: 33789085)

  • 1. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.
    Kuzmina A; Khalaila Y; Voloshin O; Keren-Naus A; Boehm-Cohen L; Raviv Y; Shemer-Avni Y; Rosenberg E; Taube R
    Cell Host Microbe; 2021 Apr; 29(4):522-528.e2. PubMed ID: 33789085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.
    Xie X; Liu Y; Liu J; Zhang X; Zou J; Fontes-Garfias CR; Xia H; Swanson KA; Cutler M; Cooper D; Menachery VD; Weaver SC; Dormitzer PR; Shi PY
    Nat Med; 2021 Apr; 27(4):620-621. PubMed ID: 33558724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
    Tada T; Dcosta BM; Samanovic MI; Herati RS; Cornelius A; Zhou H; Vaill A; Kazmierski W; Mulligan MJ; Landau NR
    mBio; 2021 Jun; 12(3):e0069621. PubMed ID: 34060334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
    Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity.
    Kuzmina A; Wattad S; Engel S; Rosenberg E; Taube R
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
    Garcia-Beltran WF; Lam EC; St Denis K; Nitido AD; Garcia ZH; Hauser BM; Feldman J; Pavlovic MN; Gregory DJ; Poznansky MC; Sigal A; Schmidt AG; Iafrate AJ; Naranbhai V; Balazs AB
    Cell; 2021 Apr; 184(9):2372-2383.e9. PubMed ID: 33743213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom.
    Wu J; Zhang L; Zhang Y; Wang H; Ding R; Nie J; Li Q; Liu S; Yu Y; Yang X; Duan K; Qu X; Wang Y; Huang W
    Front Immunol; 2021; 12():687869. PubMed ID: 34220844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.
    Zhou H; Dcosta BM; Samanovic MI; Mulligan MJ; Landau NR; Tada T
    mBio; 2021 Aug; 12(4):e0138621. PubMed ID: 34311587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
    Planas D; Bruel T; Grzelak L; Guivel-Benhassine F; Staropoli I; Porrot F; Planchais C; Buchrieser J; Rajah MM; Bishop E; Albert M; Donati F; Prot M; Behillil S; Enouf V; Maquart M; Smati-Lafarge M; Varon E; Schortgen F; Yahyaoui L; Gonzalez M; De Sèze J; Péré H; Veyer D; Sève A; Simon-Lorière E; Fafi-Kremer S; Stefic K; Mouquet H; Hocqueloux L; van der Werf S; Prazuck T; Schwartz O
    Nat Med; 2021 May; 27(5):917-924. PubMed ID: 33772244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
    Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
    Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of human post-vaccination SARS-CoV-2 standard reference sera.
    Xiang J; Katz L; Winokur PL; Chaudhary A; Digmann B; Bradford R; Rashid S; Ghosh S; Robertson A; Menetski J; Xu M; Gao P; Chen CZ; Lee T; Poelaert B; Eastman RT; Hall MD; Stapleton JT
    J Immunol Methods; 2024 Jul; 530():113698. PubMed ID: 38823574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
    Chen RE; Zhang X; Case JB; Winkler ES; Liu Y; VanBlargan LA; Liu J; Errico JM; Xie X; Suryadevara N; Gilchuk P; Zost SJ; Tahan S; Droit L; Turner JS; Kim W; Schmitz AJ; Thapa M; Wang D; Boon ACM; Presti RM; O'Halloran JA; Kim AHJ; Deepak P; Pinto D; Fremont DH; Crowe JE; Corti D; Virgin HW; Ellebedy AH; Shi PY; Diamond MS
    Nat Med; 2021 Apr; 27(4):717-726. PubMed ID: 33664494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity.
    Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.
    Wahid M; Jawed A; Mandal RK; Dailah HG; Janahi EM; Dhama K; Somvanshi P; Haque S
    Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5857-5864. PubMed ID: 34604978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.
    Carreño JM; Alshammary H; Tcheou J; Singh G; Raskin AJ; Kawabata H; Sominsky LA; Clark JJ; Adelsberg DC; Bielak DA; Gonzalez-Reiche AS; Dambrauskas N; Vigdorovich V; ; Srivastava K; Sather DN; Sordillo EM; Bajic G; van Bakel H; Simon V; Krammer F
    Nature; 2022 Feb; 602(7898):682-688. PubMed ID: 35016197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.
    Zhang L; Cui Z; Li Q; Wang B; Yu Y; Wu J; Nie J; Ding R; Wang H; Zhang Y; Liu S; Chen Z; He Y; Su X; Xu W; Huang W; Wang Y
    Commun Biol; 2021 Oct; 4(1):1196. PubMed ID: 34645933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.